Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
AstraZeneca: £7bn added to drug-maker's value; brokers have their say
08:37am, Thursday, 09'th Feb 2023
The market value of AstraZeneca PLC (LSE:AZN) shot up by nearly £7bn following the release of its fourth-quarter and full-year figures. Although the top-line number in Q4 was slightly below expectati
As demand for Covid vaccines falls, AstraZeneca lines up 'blockbuster' products for 2023
07:55am, Thursday, 09'th Feb 2023
Demand for Covid-19 vaccines has dropped, but AstraZeneca has "blockbuster" projects in development that are set to make billions of dollars, according to its CFO.
AstraZeneca PLC modestly undershoots consensus in the fourth quarter; targeting low double digit sales growth this year
03:10am, Thursday, 09'th Feb 2023
Drug maker AstraZeneca PLC (LSE:AZN)'s fourth quarter numbers marginally undershot consensus as it felt the impact of declining sales of its Covid vaccine. Total revenues for the three months ended De
AstraZeneca Q4 revenue just shy of analyst estimates
02:15am, Thursday, 09'th Feb 2023
AstraZeneca on Thursday posted fourth-quarter revenue just shy of analyst estimates, with slightly lower-than-expected sales of its best-selling oncology and rare blood disorder drugs.
AstraZeneca, BAT, Unilever and Compass lead a busy Thursday
11:00am, Wednesday, 08'th Feb 2023
A pretty busy DAY for London blue-chip share followers. Top of the table is AstraZeneca PLC (LSE:AZN), biggest company in the FTSE 100 over Shell by a few billion.
Beat the Dow Jones With This Unstoppable Dividend Stock
10:50am, Wednesday, 08'th Feb 2023 The Motley Fool
This pharmaceutical company has outperformed the Dow Jones index over the last 10 years.
Beat the Dow Jones With This Unstoppable Dividend Stock
05:50am, Wednesday, 08'th Feb 2023
This pharmaceutical company has outperformed the Dow Jones index over the last 10 years.
AstraZeneca (AZN) to Report Q4 Earnings: What's in the Cards?
03:26pm, Tuesday, 07'th Feb 2023 Zacks Investment Research
Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso and Imfinzi and Farxiga are expected to have driven sales, partially offset by lower sales of legacy drugs.
AstraZeneca says Forxiga approved in EU for heart failure
08:11am, Tuesday, 07'th Feb 2023 MarketWatch
AstraZeneca PLC said Tuesday that Forxiga has been approved in the European Union for the treatment of symptomatic chronic heart failure.
AstraZeneca says Forxiga approved in EU for heart failure
03:11am, Tuesday, 07'th Feb 2023
AstraZeneca PLC said Tuesday that Forxiga has been approved in the European Union for the treatment of symptomatic chronic heart failure.
Is Gilead Sciences a Good Stock to Buy Now?
10:41am, Monday, 06'th Feb 2023 The Motley Fool
Gilead Sciences' breast cancer drug, Trodelvy, just took a big step forward.
Top 5 Health Care Stocks That May Rally
06:35pm, Friday, 03'rd Feb 2023 Benzinga
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock's strength on days when prices go
Top 5 Health Care Stocks That May Rally - AstraZeneca (NASDAQ:AZN), Amgen (NASDAQ:AMGN)
01:35pm, Friday, 03'rd Feb 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know
11:00pm, Thursday, 02'nd Feb 2023 Zacks Investment Research
Astrazeneca (AZN) closed the most recent trading day at $63.15, moving -0.65% from the previous trading session.
GSK's Daprodustat Drug for Anemia Due to CKD Gets FDA Nod
07:18pm, Thursday, 02'nd Feb 2023 Zacks Investment Research
GSK announces the FDA approval of daprodustat for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis for at least four months.
